PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached
PharmaLogic is buying Lantheus' contract manufacturing unit and Springfield, New Jersey radiopharmaceutical plant, plus a long-term deal to make lutetium Lu 177 dotatate for Lantheus. Radioligand developers looking for capacity should ask how much of the plant's capacity is still open.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
A long-term supply contract attached to a plant sale could help keep costly hot-cell capacity in use. According to Grand View Research, committed supply agreements are among the tools that help providers align capital spending with customer development milestones.
Radioligand developers evaluating PharmaLogic's Agilera unit should ask how much Springfield capacity the lutetium Lu 177 dotatate contract will take up and how much is left for new programs.
Two pending transactions shape what to watch next: regulatory review and closing conditions for the PharmaLogic purchase, and Curium’s August offer of upward of $8 billion for Lantheus, which is still closing.
Free workspace
Turn your Sciences expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
PharmaLogic Holdings has agreed to buy Lantheus Holdings' contract manufacturing business and its radiopharmaceutical plant in Springfield, New Jersey. PharmaLogic announced the definitive agreement on November 9. The transaction includes a long-term supply agreement under which Agilera, PharmaLogic's therapeutic CDMO business, will manufacture lutetium Lu 177 dotatate for Lantheus. Financial terms were not disclosed.
The timing matters. Fraiser Kansteiner of Fierce Pharma reported that Curium offered upward of $8 billion for Lantheus in August, and that deal is still closing. Lantheus is reorganizing its manufacturing while its own ownership changes. In Contract Pharma, Charlie Sternberg described the sale as a way for Lantheus to keep access to manufacturing capacity while it concentrates on its radiopharmaceutical portfolio.
Anyone who sources radioligand manufacturing can use this deal as a worked example of how capacity changes hands in this field. The plant goes to a specialist, and its anchor product stays on the schedule.
A plant with work already booked
Springfield focuses on theranostic manufacturing, research and clinical development, and its staff is expected to move to Agilera at closing. On paper, that is a capacity purchase. The supply agreement makes it something more specific. Lantheus is selling the building and keeping a claim on its output, and PharmaLogic is buying a plant that arrives with a commercial product already on the production schedule.
The two companies already work together. In PharmaLogic's announcement, Lantheus CEO Mary Anne Heino described a long-standing relationship and said PharmaLogic has been an important manufacturing partner for Lantheus' PET products. Contract Pharma reported that she said PharmaLogic's expertise and manufacturing infrastructure make it well positioned to support reliable supply of Lantheus' recently approved radiotherapeutic products. That suggests the supply agreement could carry a relationship built on PET products into therapeutics.
Fierce Pharma noted that lutetium Lu 177 dotatate is the radioligand Novartis sells as Lutathera for neuroendocrine tumors. It was recently approved by the FDA as a generic for the first time, with that distinction going to Curium and its so-called radioligand equivalent, Bexlutry. The sources do not say how volumes under the new agreement will be split or scheduled.
Market research explains why booked volume matters so much in this business. Grand View Research's 2026 to 2033 radiopharmaceutical CDMO report says adding capacity means paying for shielded hot cells, controlled ventilation, aseptic filling, radioactive waste handling and specialized analytical equipment. That equipment only starts earning money once the facility is qualified and customer processes are transferred and validated. If a program is delayed, suites can sit underused. The firm lists capacity reservations, minimum-volume commitments and committed supply agreements as ways to match spending to demand.
The market Springfield is joining
Grand View Research
One reading is that the Springfield sale works much like a capacity reservation, with a supply agreement attached to the site. Grand View notes that installed capacity carries operating costs before utilization matures. A sponsor's external manufacturing lead comparing CDMOs can take a sharper question from this: how much of a provider's qualified capacity is already promised to an anchor customer, and how much is actually available?
Agilera's Norway base meets New Jersey
The buyer has scale in this field. Agilera began as a subsidiary of Norway's Institute for Energy Technology. Fierce Pharma reported that PharmaLogic took a majority stake last April, when Agilera had delivered more than 600,000 doses to patients in the US, Europe and Asia. According to Kalkine Media, PharmaLogic's filings describe Agilera as the sole cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries worldwide, and say Agilera brings more than 15 years of expertise in radioligand therapy development and commercialization. PharmaLogic runs more than 45 facilities across the US, Puerto Rico, Canada and Norway. It calls itself the only independent CDMO of scale in North America dedicated solely to radiopharmaceuticals.
Adding Springfield gives Agilera a US site focused on theranostic manufacturing, research and clinical development. PharmaLogic says the combination creates the first transatlantic CDMO platform dedicated to radioligand therapies, covering early clinical development through commercial manufacturing and global supply. Sponsors may want to ask directly which work will be done in Norway and which in New Jersey.
Radiopharmaceutical schedules start from the activity a patient needs at the time of the dose and work backward through transport, batch release, testing, filling and radiolabeling, according to Grand View Research. Every hour of transit uses up product. That is why having production sites close to patients matters more here than for a conventional injectable.
For developers planning US commercial supply, that decay math explains why a US therapeutic site is a meaningful addition for a CDMO that already has a European base. It matters most for developers whose patients and treatment centers are concentrated in the US.
The build-your-own option
Fierce Pharma reported that Bristol Myers Squibb committed $173 million in August, through its RayzeBio unit, to build a new 225,000-square-foot radiopharmaceutical plant in Whitestown, Indiana. The site is about 20 miles from RayzeBio's existing facility in Indianapolis. RayzeBio's lead candidate, RYZ101, is in phase 3 testing for gastroenteropancreatic neuroendocrine tumors, and BMS posted positive topline results in October.
That points to where the contract model fits and where it doesn't. A company with a late-stage lead asset and the money to back it can justify owned capacity it fully controls. For developers with earlier or less certain programs, the qualification costs and utilization risk Grand View describes make a CDMO with qualified hot cells and an existing commercial customer more attractive.
Questions to ask Agilera before closing
Sponsors already talking with PharmaLogic, or considering Springfield for a radioligand program, can raise three points now:
- How much of Springfield's qualified capacity will the Lu 177 dotatate agreement use, and what is left for clinical and commercial programs from other sponsors?
- Which development, manufacturing and release steps will be done in New Jersey, and which in Norway, for a program bound for US patients?
- How will process knowledge and technology transfer work when a program moves from early clinical work at one site to commercial supply at another?
The deal still needs regulatory review and has to meet customary closing conditions. No timeline has been announced, and both companies will operate independently until it closes. PharmaLogic was advised by Leerink Partners and Goodwin Procter, and Lantheus by Solomon Partners Securities and Covington & Burling. The next thing to watch is whether the supply agreement gets fully underway alongside the Curium transaction. When it does, Springfield's first months under Agilera will show how much of the plant's capacity is open to new programs.
Sources
- PharmaLogic Acquires Lantheus CDMO Unit, Expands U.S. Radiopharma Capacity ↗ · Contract Pharma
- PharmaLogic purchases Lantheus' radiopharma CDMO biz, plant ↗ · Fierce Pharma
- PharmaLogic to acquire Lantheus CDMO unit in New Jersey ↗
- PharmaLogic to Acquire Lantheus' CDMO Unit and Springfield ... ↗
- Radiopharmaceutical CDMO Market Size Report, 2026-2033 ↗
Featured companies
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.